Rotavirus vaccination: A concise review

Clinical Microbiology and Infection

Volumn 18, Issue SUPPL. 5, 2012, Pages 57-63

  Vesikari, T ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Effectiveness; Efficacy; Implementation; Rotavirus; Vaccination

Indexed keywords

BOVINE ROTAVIRUS VACCINE; ROTAVIRUS VACCINE; SIMIAN ROTAVIRUS VACCINE; UNCLASSIFIED DRUG;

AFRICA; AUSTRALIA; AUSTRIA; BELGIUM; BOVINE DIARRHEA VIRUS; BRAZIL; COST BENEFIT ANALYSIS; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EUROPE; FEVER; FINLAND; GASTROENTERITIS; GENETIC REASSORTMENT; GERMANY; HEALTH CARE PLANNING; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INTUSSUSCEPTION; LICENCE; LUXEMBOURG; MEXICO; MORTALITY; PRIORITY JOURNAL; REVIEW; ROTAVIRUS; ROTAVIRUS GASTROENTERITIS; ROTAVIRUS INFECTION; SOUTH AFRICA; SOUTH AND CENTRAL AMERICA; UNITED STATES; VACCINATION; VIRAL GASTROENTERITIS;

BOVINAE; HUMAN ROTAVIRUS A; ROTAVIRUS;

EID: 84867395377     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2012.03981.x     Document Type: Review

References (51)

1. Soares-Weiser K, MacLehose H, Bergman H et al. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database of Systematic Reviews 2012, Issue 2. Art. No.: CD008521. DOI: 10.1002/14651858.CD008521.pub2.
2. Bishop RF, Davidson GP, Holmes IH, Ruck BJ. Virus particles in epithelial cells of duodenal mucosa from children with acute non-bacterial gastroenteritis. Lancet 1973; 2: 1281-1283.
3. Flewett TH, Bryden AS, Davies H. Letter: Virus particles in gastroenteritis. Lancet 1973; 2: 1497.
4. Kapikian AZ, Kim HW, Wyatt RG et al. Human reovirus-like agent as the major pathogen associated with "winter" gastroenteritis in hospitalized infants and young children. N Engl J Med 1976; 294: 965-972.
5. Vesikari T, Mäki M, Sarkkinen HK, Arstila PP, Halonen PE. Rotavirus, adenovirus and non-viral enteropathogens in diarrhoea. Arch Dis Child, 1981; 56: 264-270.
6. Snyder JD, Merson MH. The magnitude of the global problem of acute diarrhoeal disease: a review of active surveillance data. Bull World Health Organ 1982; 60: 605-613.
7. Tate JE, Burton AH, Boschi-Pinto C et al. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet 2012; 12: 136-141.
8. Delem A, Lobmann M, Zygraich N. A bovine rotavirus developed as a candidate vaccine for use in humans. J Biol Stand 1984; 12: 443-445.
9. Zissis G, Lambert JP, Marbehant P et al. Protection studies in colostrum-deprived piglets of a bovine rotavirus vaccine candidate using human rotavirus strains for challenge. J Infect Dis 1983; 148: 1061-1068.
10. Vesikari T, Joensuu J. Review of rotavirus vaccine trials in Finland. J Infect Dis 1996; 174 (suppl 1): S81-S87.
11. Vesikari T. Rotavirus vaccine studies in Europe. Acta Paediatr 1999; 426: 9-13.
12. Vesikari T, Isolauri E, D'Hondt E, Delem A, André FE, Zissis G. Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet 1984; 1: 977-981.
13. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990; 22: 259-267.
14. Vesikari T, Kapikian AZ, Delem A, Zissis G. A comparative trial of rhesus monkey (RRV-1) and bovine (RIT 4237) oral rotavirus vaccines in young children. J Infect Dis 1986; 153: 832-839.
15. Vesikari T, Rautanen T, Varis T, Beards GM, Kapikian AZ. Rhesus rotavirus candidate vaccine. Clinical trial in children vaccinated between 2 and 5months of age. Am J Dis Child, 1990; 144: 285-289.
16. Rennels MB, Losonsky GA, Young AE, Shindledecker CL, Kapikian AZ, Levine MM. An efficacy trial of the rhesus rotavirus vaccine in Maryland. The Clinical Study Group. Am J Dis Child 1990; 144: 601-604.
17. Midthun K, Greenberg HB, Hoshino Y, Kapikian AZ, Wyatt RG, Chanock RM. Reassortant rotaviruses as potential live rotavirus vaccine candidates. J Virol 1985; 53: 949-954.
18. Rennels MB, Glass RI, Dennehy PH et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group. Pediatrics 1996; 97: 7-13.
19. Joensuu J, Koskenniemi E, Pang X-L, Vesikari T. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 1997; 350: 1205-1209.
20. Pérez-Schael I, Guntiñas MJ, Pérez M et al. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N Engl J Med 1997; 23: 337.
21. Vesikari T, Karvonen A, Forrest BD, Hoshino Y, Chanock RM, Kapikian AZ. Neonatal administration of rhesus rotavirus tetravalent vaccine. Pediatr Infect Dis J 2006; 25: 118-122.
22. Ward RL. Mechanisms of protection against rotavirus in humans and mice. J Infect Dis 1996; 174 (suppl 1): S51-S58.
23. Murphy TV, Gargiullo PM, Massoudi MS et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001; 344: 561-572.
24. Simonsen L, Vlboud C, Elixhauser A et al. More on RotaShield and intussusception: the role of age at the time of vaccination. J Infect Dis 2005; 192 (suppl 1): S36-S43.
25. Bernstein DI, Sack DA, Rothstein E, Reisinger K, Ward RL. Efficacy of live attenuated human rotavirus vaccine 89-12 in infants. Lancet 1999; 354: 287-290.
26. Chang HGH, Smith PF, Ackelsberg DK et al. Intussusception, rotavirus diarrhea, and rotavirus vaccine use among children in New York State. Pediatrics 2001; 108: 54-60.
27. Vesikari T, Karvonen A, Korhonen T et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine 2004; 22: 2836-2842.
28. Vesikari T, Karvonen A, Prymula R et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2years of life in European infants: randomised, double-blind controlled study. Lancet 2007; 370: 1757-1763.
29. Phua KB, Lim FS, Lau YL et al. Safety and efficacy of human rotavirus vaccine during the first 2years of life in Asian infants: randomised, double-blind, controlled study. Vaccine 2009; 27: 5936-5941.
30. Madhi SA, Cunliffe NA, Steele D et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010; 362: 289-298.
31. Zaman K, Dang DA, Victor JC et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 376: 615-623.
32. Nakagomi T, Cuevas LE, Gurgel RQ et al. Apparent extinction of non-G2 rotavirus strains from circulation in Recife, Brazil, after the introduction of rotavirus vaccine. Arch Virol 2008; 153: 591-593.
33. Carvalho-Costa FA, Volotão EM, de Assis RMS et al. Laboratory-based rotavirus surveillance during the introduction of a vaccination program, Brazil, 2005-2009. Pediatr Infect Dis J 2011; 30: S35-S41.
34. Clark HF, Furukawa T, Bell LM, Offit PA, Perrella PA, Plotkin SA. Immune response of infants and children to low-passage bovine rotavirus (strain WC3). Am J Dis Child 1986; 140: 350-356.
35. Clark HF, Offit PA, Ellis RW et al. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. J Infect Dis 1996; 174 (suppl 1): S73-S80.
36. Vesikari T, Matson DO, Dennehy P et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354: 23-33.
37. Block SL, Vesikari T, Goveia MG et al. Efficacy, immunogenicity, and safety of a Pentavalent Human-Bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics 2007; 1: 11-18.
38. Vesikari T, Clark HF, Offit PA et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine 2006; 24: 4821-4829.
39. ®, in Finnish infants up to 3years of age: the Finnish Extension Study. Eur J Pediatr 2010; 169: 1379-1386.
40. Vesikari T, Itzler R, Karvonen A et al. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine 2009; 28: 345-351.
41. Armah GE, Sow SO, Breiman RF et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomized, double-blind, placebo-controlled trial. Lancet 2010; 376: 606-614.
42. Justino MCA, Linhares AC, Lanzieri TM et al. Effectiveness of the monovalent G1P[8] human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belém, Brazil. Pediatr Infect Dis J 2011; 30: 396-401.
43. Patel MM, López-Collada VR, Bulhões MM et al. Intussusception Risk and Health Benefits of Rotavirus Vaccination in Mexico and Brazil. N Engl J Med 2011; 364: 2283-2292.
44. Richardson V, Hernandez-Pichardo J, Quintanar-Solares M et al. Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N Engl J Med 2010; 362: 299-305.
45. Paulke-Korinek M, Rendi-Wagner P, Kundi M, Kronik R, Kollaritsch H. Universal mass vaccination against rotavirus gastroenteritis: impact on hospitalization rates in Austrian children. Pediatr Infect Dis J 2010; 29: 319-323.
46. Zeller M, Rahman M, Heylen E et al. Rotavirus incidence and genotype distribution before and after national rotavirus vaccine introduction in Belgium. Vaccine 2010; 28: 7507-7513.
47. Parashar UD, Glass RI. Rotavirus vaccines - early success, remaining questions. N Engl J Med 2009; 360: 1063-1065.
48. Lopman BA, Curns AT, Yen C, Parashar UD. Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. J Infect Dis 2011; 204: 980-986.
49. Glass RI. Unexpected benefits of rotavirus vaccination in the United States. J Infect Dis 2011; 204: 975-977.
50. Greenberg HB. Rotavirus vaccination and intussusception - act two. N Engl J Med 2011; 364: 2354-2355.
51. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354: 11-22.